Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dopamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 7/20 | 0.59 |
| ▸ | MAPT | P10636 | 5/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.59 |
| ▸ | DRD2 | P14416 | 2/20 | 0.59 |
| ▸ | DRD1 | P21728 | 2/20 | 0.59 |
| ▸ | DRD4 | P21917 | 2/20 | 0.59 |
| ▸ | DRD5 | P21918 | 2/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.59 |
| ▸ | DRD3 | P35462 | 2/20 | 0.59 |
| ▸ | RECQL | P46063 | 2/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.59 |
| ▸ | TP53 | P04637 | 2/20 | 0.59 |
| ▸ | THPO | P40225 | 2/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.59 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dopamine SCHEMBL29538557 | 1.00 | ALOX15 (0.59) | ALOX15MAPTKDM4EMAPK1ALDH1A1 | |
| Dopamine SCHEMBL50533 | 0.84 | ALOX15 (0.59) | ALOX15MAPTKDM4EMAPK1ALDH1A1 | |
| Dopamine SCHEMBL29516726 | 0.84 | ALOX15 (0.59) | ALOX15MAPTKDM4EMAPK1ALDH1A1 | |
| Dopamine SCHEMBL29516921 | 0.82 | MAPT (0.60) | ALOX15MAPTKDM4EMAPK1ALDH1A1 | |
| Dopamine SCHEMBL50427 | 0.82 | ALOX15 (0.73) | ALOX15MAPTKDM4EMAPK1ALDH1A1 | |
| Dopamine SCHEMBL29435413 | 0.82 | ALOX15 (0.73) | ALOX15MAPTKDM4EMAPK1ALDH1A1 | |
| Dopamine SCHEMBL29599861 | 0.80 | MAPT (0.74) | ALOX15MAPTKDM4EMAPK1ALDH1A1 | |
| SCHEMBL30437268 | 0.79 | TSHR (0.68) | MAPK1ALDH1A1TDP1ADRB2PTGS1 | |
| SCHEMBL107956 | 0.78 | ALOX15 (0.80) | ALOX15MAPTKDM4EMAPK1ALDH1A1 | |
| SCHEMBL30631592 | 0.78 | ALOX15 (0.80) | ALOX15MAPTKDM4EMAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4622 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216368-A1 | NOVEL METHODS | INTRA-CELLULAR THERAPIES, INC. (US) | 2024-07-04 | — | — | US | claimed |
| US-20240207259-A1 | NOVEL METHODS | INTRA-CELLULAR THERAPIES, INC. (US) | 2024-06-27 | — | — | US | claimed |
| CN-118221620-A | Benzamide phenylpiperazine radioactive compound and preparation method and application thereof | 中国科学院高能物理研究所 | 2024-06-21 | — | — | CN | claimed |
| CN-118141817-A | Application of dopamine D3 receptor ligand in preparation of anti-Alzheimer disease drugs | 武汉赛纳星辰科技有限公司 | 2024-06-07 | — | — | CN | claimed |
| CN-112778183-B | Nitrogen-containing ring derivative regulator, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2024-05-10 | — | — | CN | claimed |
| EP-4352057-A1 | NOVEL SALTS AND CRYSTALS | Intra-Cellular Therapies, Inc. (US) | 2024-04-17 | — | — | EP | claimed |
| US-11957791-B2 | Methods | INTRA-CELLULAR THERAPIES, INC. (US) | 2024-04-16 | — | — | US | claimed |
| CN-111801330-B | Fused ring compounds having dopamine D3 receptor antagonism | 盐野义制药株式会社 | 2024-04-05 | — | — | CN | claimed |
| WO-2024072930-A1 | DOPAMINE D3/D2 RECEPTOR PARTIAL AGONISTS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-04-04 | — | — | WO | claimed |
| US-20240091224-A1 | NOVEL METHODS | INTRA-CELLULAR THERAPIES, INC. (US) | 2024-03-21 | — | — | US | claimed |
| EP-0654023-A1 | 5-(2-OXYPHENYL)-PYRROLE DERIVATIVES AS DOPAMINE D3 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1995-05-24 | — | — | EP | claimed |
| WO-1995010504-A1 | 2-(1-ALKOXY-2-NAPHTHALENYL)-PYRROLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS DOPAMINE D3 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1995-04-20 | — | — | WO | claimed |
| EP-0641202-A1 | USE OF INDOLONE DERIVATIVES FOR THE TREATMENT OF MEMORY DISORDERS, SEXUAL DYSFUNCTION AND PARKINSON'S DISEASE | SMITHKLINE BEECHAM PLC (GB) | 1995-03-08 | — | — | EP | claimed |
| WO-1995004713-A1 | 2-AMINOINDANS AS SELECTIVE DOPAMINE D3 LIGANDS | THE UPJOHN COMPANY (US) | 1995-02-16 | — | — | WO | claimed |
| WO-1995004037-A1 | 2-(2-HYDROXYPHENYL)-5-(N-PHENYLMETHYL-AMINOMETHYL)-PYRROLES AS ANTIPSYCHOTIC AGENTS | SMITHKLINE BEECHAM PLC (GB) | 1995-02-09 | — | — | WO | claimed |
| WO-1995004039-A1 | 2-PHENYLPYRROLE DERIVATIVES AS DOPAMINE D3 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1995-02-09 | — | — | WO | claimed |
| WO-1995000508-A1 | PHENYRROLE DERIVATIVES AND THEIR USE AS DOPAMINE D3 ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1995-01-05 | — | — | WO | claimed |
| WO-1994010989-A1 | USE OF ALPHA-1C SPECIFIC COMPOUNDS TO TREAT BENIGN PROSTATIC HYPERPLASIA | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1994-05-26 | — | — | WO | claimed |
| WO-1994003426-A1 | 5-(2-OXYPHENYL)-PYRROLE DERIVATIVES AS DOPAMINE D3 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1994-02-17 | — | — | WO | claimed |
| WO-1993023035-A2 | USE OF INDOLONE DERIVATIVES FOR THE TREATMENT OF MEMORY DISORDERS, SEXUAL DYSFUNCTION AND PARKINSON'S DISEASE | SMITHKLINE BEECHAM PLC (GB) | 1993-11-25 | — | — | WO | claimed |